Skip to main content
OpenTrials
Completed

NCT Number: NCT00859560

Retrospective Survey of Bone Fracture in Patients With Arimidex 1mg

The retrospective survey is to investigate the incidence of bone fracture in post-menopausal breast cancer patients with Arimidex 1mg, who were previously registered for the clinical experience investigation.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Post-menopausal breast cancer patients treated with Arimidex 1mg at the time of previously conducted clinical experience investigation.

Exclusion criteria

-

Treatment and study plan

Primary outcomes

  1. Bone fracture incidence

    Time frame: Time since starting Arimidex

Secondary outcomes

  1. Survival

    Time frame: Time since starting Arimidex

  2. Bone density measurement

    Time frame: Time since starting Arimidex

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Retrospective Survey of Bone Fracture in Post-Menopausal Breast Cancer Patients With Arimidex 1 mg as Adjuvant Therapy

Important dates

Study start
2008
Study completion
2008
First posted
Mar 11, 2009
Registry last updated
Mar 11, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.